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Abstract
The issue of determining not only an adequate dose but also a dosing frequency
of a drug arises frequently in Phase II clinical trials. This results in the comparison
of models which have some parameters in common. Planning such studies based on
Bayesian optimal designs offers robustness to our conclusions since these designs,
unlike locally optimal designs, are efficient even if the parameters are misspecified.
In this paper we develop approximate design theory for Bayesian D-optimality for
nonlinear regression models with common parameters and investigate the cases of
common location or common location and scale parameters separately. Analytical
characterisations of saturated Bayesian D-optimal designs are derived for frequently
used dose-response models and the advantages of our results are illustrated via a
numerical investigation.
1 Introduction
One of the key objectives in pharmaceutical drug development is to properly characterise
the dose-response relationship as this has a direct impact on the determination of an
efficacious and safe dose in Phase II clinical trials. As pointed out by Dette et al. (2008)
and Bretz et al. (2010), too high of a dose is likely to result in toxicity and safety problems
whereas choosing too low of a dose reduces the chance of establishing adequate efficacy
and thus the chance of approval of the drug. In fact, in a recent review Sacks et al. (2014)
identify the failure to select an optimal dose due to statistical uncertainty as one of the
most frequent reasons for the delay or denial of approval of drugs by the Food and Drug
Administration (FDA).
The efficient planning of dose-finding studies can significantly improve the statistical ac-
curacy for the selection of an efficacious and safe dose. For this reason numerous authors
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investigate the construction of optimal experimental designs for such studies and consider
regression models which are frequently used to describe the dose-response relationship
(see, for example, Dette et al. (2008), Dragalin et al. (2008) and Bretz et al. (2010)).
In this paper we consider the closely related issue of determining not only a safe and
efficacious dose but also the dosing frequency. This is often of interest in Phase II dose-
finding studies since the frequency of administration affects the pharmacological effect of
the drug under investigation. That is, if the same drug is administered at different dosing
intervals, for example, once or twice a day, the drug exposure inside the body during the
day will be higher right after administration and lower right before administration in the
case of once a day administration whereas if the drug is administered twice a day the
drug exposure during the day will be more uniform.
Under this scenario, estimating the dose-response curves corresponding to the different
administration frequencies separately is inefficient. This is due to the fact that the regres-
sion models will often have common parameters thus suggesting a borrowing of strength.
One of the parameters that it is reasonable to assume is the same for all models is the
parameter corresponding to the placebo effect. Another assumption that is made in some
situations is that there exists a biological maximum attainable drug effect. In this case,
the parameter describing the efficacy for high doses can also be considered to be common
for all models. In what follows we will investigate separately the cases where only the
parameter corresponding to the placebo effect or both of the aforementioned parameters
are common in all the regression models.
The aim of the present paper is the efficient planning of such dose-finding studies where the
regression models, used to model the dose-response relationship for the different adminis-
tration frequencies, share some of the parameters. More specifically, we are interested in
finding designs providing us with the doses to utilise in the different administration groups
and also the way to split the total sample size between the groups, such that the design is
optimal in terms of estimating all of the model parameters with high precision. Despite of
the practical interest, the construction of optimal designs for dose-finding studies involv-
ing different administration frequencies has only been investigated by Feller et al. (2017)
who develop the optimal design theory corresponding to this scenario and derive explicit
expressions for locally D-optimal designs. However, locally D-optimal designs require a
best guess of the parameter values in order to be used in practice which can result in
inefficient designs if the parameters are misspecified. Therefore, a design strategy that is
robust to parameter misspecification is of great importance in applications.
Throughout this paper we adopt the robust design strategy of Bayesian optimal designs
introduced by Pronzato and Walter (1985), Chaloner (1989) and Chaloner and Larntz
(1989). Given an uncertainty space for the parameter values, Bayesian optimality incor-
porates this uncertainty in the formulation of the optimality criteria via a prior distri-
bution on the given parameter space and the resulting Bayesian optimality criteria are
based on classical optimality criteria (see, for example, Chaloner (1993) and Chaloner
and Verdinelli (1995) for more details). The construction of Bayesian optimal designs for
several regression models has been studied, for example, by Dette et al. (2007), Dette
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et al. (2008) and Chaloner and Larntz (1992). However, to the best of the authors knowl-
edge, Bayesian optimal designs for dose-finding studies involving several administration
frequency groups have not been considered in the literature.
In the present paper we consider the Bayesian D-optimal design problem for comparing
regression models with common parameters. Since these designs are based on the results
for the individual models, in Section 2 we derive analytical characterisations of Bayesian
D-optimal designs for the individual regression models which, to the best of our knowledge,
do not exist in the literature so far. In Section 3 we introduce the regression models with
common parameters and in Section 3.1 we derive some general results concerning the
Bayesian D-optimal designs. The scenarios where the regression models have only the
location parameter or both the location and scale parameter in common are considered in
Sections 3.2 and 3.3, respectively. In both cases, we provide explicit characterisations of
the saturated Bayesian D-optimal designs for regression models that are frequently used
in dose-response studies. Finally, in Section 4 we asses the performance of the saturated
designs constructed in Section 3 in a situation where they are not globally optimal.
2 Bayesian D-optimal designs for individual regres-
sion models
It turns out that the locally optimal designs for models with common parameters are
based on the locally optimal designs for the individual models. Therefore, we begin our
investigation by considering the construction of Bayesian optimal designs for individual
regression models. Besides some results for specific regression models, the construction of
such designs in a general framework has not been considered in the literature so far.
2.1 Models and optimality criterion
We consider regression models of the form
Yjl = f(dj, θ˜) + εjl, j = 1, . . . , k˜; l = 1, . . . , n˜j, (2.1)
where εjl are independent centred normally distributed, that is, εjl
iid∼ N(0, σ2),
θ˜ = (θ1, . . . , θm˜)
T ∈ Θ˜ ⊂ Rm˜ is the vector of model parameters and n˜j is the total
number of observations taken at each dose level dj (j = 1, . . . , k˜) taking values in the
design space X = [0, dmax]. We collect the information provided by the different dose
levels in a probability measure, say ξ˜, on the design space X defined as
ξ˜ =
{
d1 . . . dk˜
ω1 . . . ωk˜
}
, 0 < ωj < 1,
k˜∑
j=1
ωj = 1,
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(see Kiefer (1974)). The measure ξ˜ is called design, the dj’s are called the support points
of the design and the corresponding ωj’s are the weights of the design and represent the
proportion of observations to be taken at each experimental condition dj. We denote the
support of the design ξ˜ by supp(ξ˜). Let n˜ =
∑k˜
j=1 n˜j be the total sample size. Under the
assumption
lim
n→∞
n˜j
n˜
= ωj > 0, j = 1, . . . , k˜,
the maximum likelihood estimator ˆ˜θ of the parameter vector θ˜ satisfies
√
n˜(ˆ˜θ − θ˜) D−→ Nm˜(0,M−1ind(ξ˜, θ˜)),
where
M−1ind(ξ˜, θ˜) =
∫
X
h˜(d, θ˜)h˜T (d, θ˜)dξ˜(d), (2.2)
and
h˜(d, θ˜) =
1
σ
(
∂
∂θ˜
f(d, θ˜)
)T
. (2.3)
Our goal is to find optimal designs of this form such that the parameter vector θ˜ is esti-
mated with high precision even when there is imperfect knowledge of the true parameter
values.
As discussed in the introduction, throughout this paper we adopt the Bayesian approach as
a robust design strategy and thus we address the issue of parameter dependence of locally
optimal designs. Since interest is in estimating all of the model parameters, the Bayesian
criterion is based on the classical D-optimality criterion (see Chaloner and Verdinelli
(1995) for more details). In particular, if p˜i is a prior distribution on the parameter space
Θ˜, a design ξ˜∗p˜i is called Bayesian D-optimal with respect to the prior p˜i for the individual
model (2.1) if it maximises the function
Φp˜i(ξ˜) =
∫
Θ˜
log det{Mind(ξ˜, θ˜)} p˜i(dθ˜). (2.4)
2.2 Bayesian D-optimal designs
A very important tool for characterising and checking the optimality of a candidate design
is the general equivalence theorem. Using Theorem 3.3 in Dette et al. (2007) the general
equivalence theorem for Bayesian D-optimality of models of the form (2.1) is given below.
Theorem 2.1. A design ξ˜∗p˜i is Bayesian D-optimal with respect to the prior p˜i for maxi-
mum likelihood estimation in model (2.1) if and only if the inequality∫
Θ˜
g(d, ξ˜∗p˜i, θ˜) p˜i(dθ˜) :=
∫
Θ˜
hT (d, θ˜)M−1ind(ξ˜
∗
p˜i, θ˜)h(d, θ˜)p˜i(dθ˜) ≤ m˜,
holds for all d ∈ X = [0, dmax]. Equality holds for any point d ∈ supp(ξ˜∗p˜i).
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An approximate design for maximum likelihood estimation in model (2.1) must have
at least m˜ support points in order to be estimable for all the model parameters. A well
known result in the optimal design theory is that of equally weighted D-optimal saturated
designs, that is, of designs with as many support points as model parameters. Lemma 2.1
shows that this result holds also in the case of Bayesian D-optimal saturated designs for
maximum likelihood estimation in model (2.1) and it is proven in the appendix.
Lemma 2.1. If ξ˜∗p˜i is a Bayesian D-optimal saturated design with respect to the prior
p˜i for maximum likelihood estimation in model (2.1), then it has equal weights 1
m˜
at its
support points.
For the rest of this section we will focus on three well-known nonlinear models which are
widely used for the modelling of the dose-response relationship. Namely, we consider the
Emax, the exponential and the linear-in-log models specified by the regression functions
f1(d, θ˜) = θ0 +
θ1d
θ2 + d
, d ∈ [0, dmax], (2.5)
f2(d, θ˜) = θ0 + θ1
(
exp
(
d
θ2
)
− 1
)
, d ∈ [0, dmax], (2.6)
f3(d, θ˜) = θ0 + θ1 log
(
d
θ2
+ 1
)
, d ∈ [0, dmax], (2.7)
respectively. The locally D-optimal designs for reparameterisations of these models are
found in Dette et al. (2010) and are proven to be saturated, that is, they have exactly
three support points, with the end-points of the design space always being two of the
support points. Therefore, for each of the nonlinear models given above, we consider
the construction of Bayesian D-optimal saturated designs for which we provide analyti-
cal characterisations presented in the following theorem. Its proof can be found in the
appendix.
Theorem 2.2. A Bayesian D-optimal saturated design with respect to the prior p˜i =
p˜i0 × p˜i1 × p˜i2 for maximum likelihood estimation in the Emax, exponential or the linear-
in-log model is equally supported at points 0, d˜∗, dmax where the non-trivial support point
d˜∗ is a solution in the interval (0, dmax) of the equation∫
Θ˜2
(
1
d
− 1
dmax − d −
2
θ2 + d
)
p˜i2(dθ2) = 0, (2.8)
for the Emax model, of the equation∫
Θ˜2
exp(d/θ2) (dmax exp(dmax/θ2)− (d+ θ2)(exp(dmax/θ2)− 1))
dmax exp(dmax/θ2)(exp(d/θ2)− 1)− d exp(d/θ2)(exp(dmax/θ2)− 1) p˜i2(dθ2) = 0
(2.9)
for the exponential model and of the equation∫
Θ˜2
1
d+ θ2
θ2 log(dmax/θ2 + 1)(dmax + θ2)− dmax(d+ θ2)
d(dmax + θ2) log(dmax/θ2 + 1)− dmax(d+ θ2) log(d/θ2 + 1) p˜i2(dθ2) = 0, (2.10)
for the linear-in-log model.
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Note that these analytical characterisations reduce the design problem to solving an equa-
tion in one variable and therefore, the numerical effort for design search is reduced sub-
stantially. Furthermore, the Bayesian D-optimal designs require only the marginal prior
distribution p˜i2 on Θ˜2, that is, they require prior information only for the parameter θ2
and not for the full parameter vector, because the considered models are linear in the first
two parameters θ0 and θ1.
3 Bayesian D-optimal designs for regression models
with common parameters
In this section we focus on our core investigation regarding the case of M different admin-
istration frequency groups modelled using the same parametric form and as it is discussed
in the introduction, these models could share some parameters while others are different.
More precisely, we consider regression models of the form
Yijl = f(d
(i)
j ,θ1,θ
(i)
2 ) + εijl, i = 1, . . . ,M ; j = 1, . . . , ki; l = 1, . . . , nij, (3.1)
where εijl
iid∼ N(0, σ2i ) and in each administration frequency group i = 1, . . . ,M a total
of nij observations are taken at each dose level d
(i)
1 , . . . , d
(i)
ki
. We further assume that
the dose levels d
(i)
j , i = 1, . . . ,M ; j = 1, . . . , ki, vary in possibly different design spaces
for each group, that is, Xi = [0, d(i)max], i = 1, . . . ,M . The vector θ1 = (θ1, . . . , θp)T ∈
Θ1 ⊂ Rp corresponds to the parameters that are the same in all groups whereas θ(i)2 =
(θ
(i)
1 , . . . , θ
(i)
q )T ∈ Θ(i)2 ⊂ Rq, i = 1, . . . ,M , is the vector of parameters that are different
for different groups.
3.1 General results
Planning a dose-finding study with different administration frequency groups is concerned
with identifying the doses to be utilised in each group and also identifying how to split
the total sample size between the groups. We formulate this using approximate designs
in the sense of Kiefer (1974). In particular, for each group i = 1, . . . ,M , we define the
approximate design
ξi =
{
d
(i)
1 . . . d
(i)
ki
ωi1 . . . ωiki
}
, 0 < ωij < 1,
ki∑
j=1
ωij = 1,
as a probability measure on the design space Xi assigning a proportion ωij of the ob-
servations in the ith group at each of the dose levels d
(i)
j (i = 1, . . . ,M ; j = 1, . . . , ki).
Furthermore, we define the probability measure
µ =
{
1 . . . M
λ1 . . . λM
}
, 0 < λi < 1,
M∑
i=1
λi = 1,
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on the set {1, . . . ,M} assigning a proportion λi of the total sample size to the ith group.
The collection of these designs in the vector ξ = (ξ1, . . . , ξM , µ) is a probability measure
on the design space X1 × . . .XM × {1, . . . ,M} and is also called a design throughout this
paper.
As discussed in the introduction, estimating the dose-response curves corresponding to
each group separately, using the results of section 2, is wasteful because of the bor-
rowing of strength due to the common parameters in the models. We therefore con-
sider the simultaneous maximum likelihood estimation of the full parameter vector θ =
(θ1,θ
(1)
2 , . . . ,θ
(M)
2 )
T ∈ Θ1 ×Θ(1)2 × . . .Θ(M)2 = Θ ⊂ Rm where m = p+ qM .
Let ni =
∑ki
j=1 nij be the sample size in the ith group and denote by n =
∑M
i=1 ni the total
sample size. From Feller et al. (2017) we have that under common regularity assumptions
and the assumptions
lim
ni→∞
nij
ni
= ωij and lim
n→∞
ni
n
= λi (i = 1, . . . ,M ; j = 1, . . . , ki),
the maximum likelihood estimator θˆ of the full parameter vector θ satisfies
√
n(θˆ − θ) D−→ Nm(0,M−1(ξ,θ)),
where
M(ξ,θ) =
∫ ∫
Xz
hz(d,θ)h
T
z (d,θ)dξz(d)dµ(z) =
M∑
i=1
λiM
(i)(ξi,θ), (3.2)
is the information matrix of the design ξ = (ξ1, . . . , ξM , µ), the matrices M
(i) are defined
as
M (i)(ξi,θ) =
∫
Xi
hi(d,θ)h
T
i (d,θ)dξi(d), i = 1, . . . ,M, (3.3)
and
hi(d,θ) =
1
σi
( ∂
∂θ1
f(d,θ1,θ
(i)
2 )
)T
,0Tq(i−1),
(
∂
∂θ
(i)
2
f(d,θ1,θ
(i)
2 )
)T
,0Tq(M−i)
T ∈ Rm,
(3.4)
is the gradient of the regression function f(d,θ1,θ
(i)
2 ) with respect to the parameter vector
θ ∈ Rm, with 0q(i−1) ∈ Rq(i−1) and 0q(M−i) ∈ Rq(M−i) denoting vectors with all entries
equal to zero.
Let pi be a prior distribution on the parameter space Θ = Θ1 ×Θ(1)2 × . . .Θ(M)2 . A design
ξ∗pi is Bayesian D-optimal with respect to the prior pi for maximum likelihood estimation
in models (3.1) if it maximises
Φpi(ξ) =
∫
Θ
log det{M(ξ,θ)}pi(dθ). (3.5)
The following theorem provides the general equivalence theorem for characterising and
checking the Bayesian D-optimality of a candidate design in the multiple administration
frequency groups scenario we consider. Its proof is given in the appendix.
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Theorem 3.1. A design ξ∗pi = (ξ
∗
1 , . . . , ξ
∗
M , µ
∗) is Bayesian D-optimal with respect to the
prior pi for maximum likelihood estimation in models (3.1), if and only if the M inequalities
τi(d) =
∫
Θ
gi(d, ξ
∗
pi,θ)pi(dθ)−m :=
∫
Θ
hTi (d,θ)M
−1(ξ∗pi,θ)hi(d,θ)pi(dθ)− (p+ qM) ≤ 0,
(3.6)
are satisfied for all d ∈ Xi, i = 1, . . . ,M . Equality holds for any points (d1, . . . , dM , z) ∈
supp(ξ∗1)× . . .× supp(ξ∗M)× supp(µ∗).
Now let
ΞMm =
{
ξpi = (ξ1, . . . , ξM , µ)|
M∑
i=1
|supp(ξi)| = m
}
, (3.7)
be the set of all designs on X1 × . . . × XM × {1, . . . ,M}, with a total of exactly m
different dose levels in the M groups. Therefore, this is the class of saturated designs
on X1 × . . . × XM × {1, . . . ,M}. Lemma 3.1 provides us with the weights of Bayesian
D-optimal designs in the class ΞMm and is proven in the appendix.
Lemma 3.1. Let ξpi = (ξ1, . . . , ξM , µ) ∈ ΞMm denote a design on X1×. . .×XM×{1, . . . ,M}
and mi denote the number of support points of ξi (i = 1, . . . ,M). Also assume that
the m =
∑M
i=1 mi vectors h1(d
(1)
1 ,θ), . . . , h1(d
(1)
m1 ,θ), . . . , hM(d
(M)
1 ,θ), . . . , hM(d
(M)
mM ,θ) are
linearly independent for all parameters θ ∈ Θ, where d(i)j ∈ supp(ξi), j = 1, . . . ,mi; i =
1, . . . ,M .
If ξ∗pi = (ξ
∗
1 , . . . , ξ
∗
M , µ
∗) is Bayesian D-optimal with respect to the prior pi in the class ΞMm ,
then each ξ∗i has equal weights at its support points and the weights of µ
∗ at its support
points 1, . . . ,M are given by m1
m
, . . . , mM
m
respectively.
In what follows we focus on the construction of designs which are Bayesian D-optimal in
the class ΞMm , that is, of designs which are saturated. This is because these designs have
the smallest possible number of support points and thus, the number of experimental
conditions where observations should be taken is minimum. Therefore, saturated designs
result in lower costs for the study and are thus often preferred to designs which are optimal
amongst all possible designs if the latter have more support points (see Section 4 for more
details).
Moreover, in the following two sections we investigate the cases of the models (3.1) having
the same location parameter and having the same location and scale parameters sepa-
rately. Table 3.1 presents these two cases with respect to the forms of the regression
functions for the Emax, exponential and linear-in-log models.
3.2 Bayesian D-optimal designs for models with the same loca-
tion parameter
We first consider the case where the regression models corresponding to the M admin-
istration frequency groups share only the location parameter and thus, the regression
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Table 1: Emax, exponential and linear-in-log models for i = 1, . . . ,M groups. Left column:
Common location parameter. Right column: Common location and scale parameters.
location location and scale
Emax θ1 + θ
(i)
1
d
θ
(i)
2 +d
θ1 + θ2
d
θ
(i)
2 +d
Exponential θ1 + θ
(i)
1
(
exp
(
d
θ
(i)
2
)− 1) θ1 + θ2( exp ( d
θ
(i)
2
)− 1)
Linear-in-log θ1 + θ
(i)
1 log
(
d
θ
(i)
2
+ 1
)
θ1 + θ2 log
(
d
θ
(i)
2
+ 1
)
function in (3.1) is of the form
f(d, θ1,θ
(i)
2 ) = θ1 + f0(d,θ
(i)
2 ), i = 1, . . . ,M. (3.8)
This corresponds, for example, to the case of a common placebo effect for all groups. Here
the full parameter vector is θ = (θ1,θ
(1)
2 , . . . ,θ
(M)
2 )
T ∈ Θ ⊂ Rm where m = 1 + qM .
Denote by p˜i
(i)
2 the marginal prior distribution on Θ
(i)
2 (i = 1, . . . ,M). The following
theorem provides a solution of the Bayesian D-optimal design problem in the class ΞMm for
models (3.1) with regression functions (3.8) if the Bayesian D-optimal saturated designs
for the individual models are known. Its proof can be found in the appendix.
Theorem 3.2. Let σ21 = mini=1,...,M σ
2
i and consider models (3.1) with regression func-
tions of the form (3.8) also satisfying
f0(0,θ
(i)
2 ) = 0, η0(0,θ
(i)
2 ) =
∂
∂θ
(i)
2
f0(d,θ
(i)
2 )|d=0 = 0q, (i = 1, . . . ,M). (3.9)
If the saturated design
ξ˜∗
p˜i
(i)
2
=
{
0 d
(i)
1 . . . d
(i)
q
1
q+1
1
q+1
. . . 1
q+1
}
, (3.10)
is the Bayesian D-optimal saturated design with respect to the prior p˜i
(i)
2 on Θ
(i)
2 for max-
imum likelihood estimation in the individual model with variance σ2i (i = 1, . . . ,M), then
the Bayesian D-optimal design in the class Ξ25 with respect to the prior pi = p˜i1 × p˜i(1)2 ×
. . . × p˜i(M)2 for maximum likelihood estimation in models (3.1) with regression function
(3.8) is given by ξ∗pi = (ξ
∗
1 , . . . , ξ
∗
M , µ
∗), where
ξ∗1 = ξ˜
∗
p˜i
(1)
2
; ξ∗i =
{
d
(i)
1 . . . d
(i)
q
1
q
. . . 1
q
}
, i = 2, . . . ,M ; µ∗ =
{
1 2 . . . M
q+1
m
q
m
. . . q
m
}
.
(3.11)
Therefore, the common location parameter θ1 is estimated in the group with minimal
variance. Intuitively this result is reasonable since the estimator of the common location
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parameter θ1 is roughly the mean of the observations at dose level d = 0 and the variance
of this estimator is proportional to the variance in the considered group.
The corresponding Bayesian D-optimal saturated designs for the cases of Emax, expo-
nential and linear-in-log models are found explicitly and are presented in Corollary 3.1.
This result follows by a direct application of Theorem 3.2 using the corresponding char-
acterisations presented in Theorem 2.2 for Bayesian D-optimal saturated designs in the
individual Emax, exponential and linear-in-log models and thus, its proof is omitted.
Corollary 3.1. Let σ21 = mini=1,...,M σ
2
i . The Bayesian D-optimal design in the class (3.7)
with respect to the prior pi = p˜i1 × p˜i(1)2 × . . . × p˜i(M)2 for maximum likelihood estimation
in Emax, exponential and linear-in-log models (3.1) with regression functions (3.8) is
ξ∗pi = (ξ
∗
1 , . . . , ξ
∗
M , µ
∗) where
ξ∗1 =
{
0 d∗,(1) d(1)max
1
3
1
3
1
3
}
; ξ∗i =
{
d∗,(i) d(i)max
1
2
1
2
}
, i = 2, . . . ,M ; µ∗ =
{
1 2 . . . M
3
m
2
m
. . . 2
m
}
,
and the point d˜∗,(i) (i = 1, . . . ,M) is a solution of the equation (2.8), (2.9) and (2.10) for
the cases of Emax, exponential and linear-in-log individual models respectively using the
corresponding marginal prior p˜i
(i)
2 .
3.3 Bayesian D-optimal designs for models with the same loca-
tion and scale parameters
In this section we consider models (3.1) with regression functions of the form
f(d, θ1, θ2,θ
(i)
2 ) = θ1 + θ2f0(d,θ
(i)
2 ), i = 1, . . . ,M, (3.12)
that is, the models have common location and scale parameters. One such situation is,
for example, when both the placebo effect and the efficacy for high doses coincide across
the different models. As noted by Feller et al. (2017), the optimal design problem in
this case is significantly harder. Therefore, in what follows we will present results for
the case M = 2 administration frequency groups and thus the full parameter vector is
θ = (θ1, θ2, θ
(1)
2 , θ
(2)
2 )
T ∈ Θ ⊂ R4. Similar results can be obtained for M > 2 with an
additional amount of notation.
For the rest of this section we will focus on Emax, exponential and linear-in-log models for
which we derive analytical characterisations of their corresponding Bayesian D-optimal
designs. We also note that we construct Bayesian D-optimal designs in the class Ξ24,
defined in (3.7), of saturated designs on X1 × X2 × {1, 2}. We begin with the explicit
result for two Emax models with the same location and scale parameters. The proof can
be found in the appendix.
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Theorem 3.3. Let r =
σ21
σ22
and d˜∗,(i), d∗,(i) be solutions of the equation (2.8) in the interval
(0, d
(i)
max) and of the equation∫
Θ
(i)
2
1
d
− 2
d+ θ
(i)
2
p˜i
(i)
2 (dθ
(i)
2 ) = 0,
in the interval [0, d
(i)
max] respectively using in both equations the marginal prior distribution
p˜i
(i)
2 on Θ
(i)
2 for i = 1, 2. Also define the function
u(d˜∗,(1), d∗,(1), d˜∗,(2), d∗,(2)) := 2 log
[
d˜∗,(1)d(1)max(d
(1)
max − d˜∗,(1))d∗,(2)
d˜∗,(2)d(2)max(d
(2)
max − d˜∗,(2))d∗,(1)
]
+ 4
2∑
i=1
(−1)i+1
∫
Θ
(i)
2
log
[
(d∗,(i) + θ(i)2 )
(d˜∗,(i) + θ(i)2 )(d
(i)
max + θ
(i)
2 )
]
p˜i
(i)
2 (dθ
(i)
2 ).
The Bayesian D-optimal design in the class Ξ24 with respect to the prior pi = p˜i1×p˜i2×p˜i(1)2 ×
p˜i
(2)
2 for maximum likelihood estimation in two Emax models with regression functions of
the form (3.12) is
(1) ξa,∗ = (ξa,∗1 , ξ
a,∗
2 , µ
a,∗) if log r ≤ 0 and log r ≤ u(d˜∗,(1), d∗,(1), d˜∗,(2), d∗,(2)), where
ξa,∗1 =
{
0 d˜∗,(1) d(1)max
1
3
1
3
1
3
}
, ξa,∗2 =
{
d∗,(2)
1
}
, µa,∗ =
{
1 2
3
4
1
4
}
,
(2) ξb1,∗ = (ξb1,∗1 , ξ
b1,∗
2 , µ
b1,∗) if u(d˜∗,(1), d∗,(1), d˜∗,(2), d∗,(2)) < log r ≤ 0, where
ξb1,∗1 =
{
0 d∗,(1)
1
2
1
2
}
, ξb1,∗2 =
{
d˜∗,(2) d(2)max
1
2
1
2
}
, µb1,∗ =
{
1 2
1
2
1
2
}
,
(3) ξb2,∗ = (ξb2,∗1 , ξ
b2,∗
2 , µ
b2,∗) if 0 ≤ log r ≤ u(d˜∗,(1), d∗,(1), d˜∗,(2), d∗,(2)), where
ξb2,∗1 =
{
d˜∗,(1) d(1)max
1
2
1
2
}
, ξb2,∗2 =
{
0 d∗,(2)
1
2
1
2
}
, µb2,∗ =
{
1 2
1
2
1
2
}
,
(4) ξc,∗ = (ξc,∗1 , ξ
c,∗
2 , µ
c,∗) if log r ≥ 0 and log(r) > u(d˜∗,(1), d∗,(1), d˜∗,(2), d∗,(2)), where
ξc,∗1 =
{
d∗,(1)
1
}
, ξc,∗2 =
{
0 d˜∗,(2) d(2)max
1
3
1
3
1
3
}
, µc,∗ =
{
1 2
1
4
3
4
}
.
The analogous results for the cases of two exponential and two linear-in-log models with
the same location and scale parameters are presented in the following theorems. Their
proofs follow along the same lines as the proof of Theorem 3.3 and are therefore omitted.
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Theorem 3.4. Let r =
σ21
σ22
and d˜∗,(i) be a solution in the interval (0, d(i)max) of the equation
(2.9) using the marginal prior distribution p˜i
(i)
2 on Θ
(i)
2 . Also define the function
u(d˜∗,(1), d˜∗,(2))
:= 2
2∑
i=1
(−1)i+1
∫
Θ
(i)
2
2 log
[(
1− d˜∗,(i)
d
(i)
max
)
exp
(
d˜∗,(i)
θ
(i)
2
)
+ d˜
∗,(i)
d
(i)
max
exp
(
d˜∗,(i)−d(i)max
θ
(1)
2
)
− 1
]
p˜i
(i)
2 (dθ
(i)
2 )
The Bayesian D-optimal design in the class Ξ24 with respect to the prior pi = p˜i1 × p˜i2 ×
p˜i
(1)
2 × p˜i(2)2 for maximum likelihood estimation in two exponential models with regression
functions of the form (3.12) is
(1) ξa,∗ = (ξa,∗1 , ξ
a,∗
2 , µ
a,∗) if log r ≤ 0 and log r ≤ u(d˜∗,(1), d˜∗,(2)), where
ξa,∗1 =
{
0 d˜∗,(1) d(1)max
1
3
1
3
1
3
}
, ξa,∗2 =
{
d
(2)
max
1
}
, µa,∗ =
{
1 2
3
4
1
4
}
,
(2) ξb1,∗ = (ξb1,∗1 , ξ
b1,∗
2 , µ
b1,∗) if u(d˜∗,(1), d˜∗,(2)) < log r ≤ 0, where
ξb1,∗1 =
{
0 d
(1)
max
1
2
1
2
}
, ξb1,∗2 =
{
d˜∗,(2) d(2)max
1
2
1
2
}
, µb1,∗ =
{
1 2
1
2
1
2
}
,
(3) ξb2,∗ = (ξb2,∗1 , ξ
b2,∗
2 , µ
b2,∗) if 0 ≤ log r < u(d˜∗,(1), d˜∗,(2)), where
ξb2,∗1 =
{
d˜∗,(1) d(1)max
1
2
1
2
}
, ξb2,∗2 =
{
0 d
(2)
max
1
2
1
2
}
, µb2,∗ =
{
1 2
1
2
1
2
}
,
(4) ξc,∗ = (ξc,∗1 , ξ
c,∗
2 , µ
c,∗) if log r ≥ 0 and log(r) > u(d˜∗,(1), d˜∗,(2)), where
ξc,∗1 =
{
d
(1)
max
1
}
, ξc,∗2 =
{
0 d˜∗,(2) d(2)max
1
3
1
3
1
3
}
, µc,∗ =
{
1 2
1
4
3
4
}
.
Theorem 3.5. Let r =
σ21
σ22
and d˜∗,(i) be a solution in the interval (0, d(i)max) of the equation
(2.10) using the marginal prior distribution p˜i
(i)
2 on Θ
(i)
2 . Also define the function
u(d˜∗,(1), d˜∗,(2))
:= 2
2∑
i=1
(−1)i+1
∫
Θ
(i)
2
log
[(
d˜∗,(i)
d˜∗,(i)+θ(i)2
)(
g(d(i)max, θ
(i)
2 )− g(d˜∗,(i), θ(i)2 )
)]
p˜i
(i)
2 (dθ
(i)
2 )
where g(d, θ2) =
d+θ2
d
log( d
θ2
+ 1). The Bayesian D-optimal design in the class Ξ24 with
respect to the prior pi = p˜i1 × p˜i2 × p˜i(1)2 × p˜i(2)2 for maximum likelihood estimation in two
linear-in-log models with regression functions of the form (3.12) is
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(1) ξa,∗ = (ξa,∗1 , ξ
a,∗
2 , µ
a,∗) if log r ≤ 0 and log r ≤ u(d˜∗,(1), d˜∗,(2)), where
ξa,∗1 =
{
0 d˜∗,(1) d(1)max
1
3
1
3
1
3
}
, ξa,∗2 =
{
d
(2)
max
1
}
, µa,∗ =
{
1 2
3
4
1
4
}
,
(2) ξb1,∗ = (ξb1,∗1 , ξ
b1,∗
2 , µ
b1,∗) if u(d˜∗,(1), d˜∗,(2)) < log r ≤ 0, where
ξb1,∗1 =
{
0 d
(1)
max
1
2
1
2
}
, ξb1,∗2 =
{
d˜∗,(2) d(2)max
1
2
1
2
}
, µb1,∗ =
{
1 2
1
2
1
2
}
,
(3) ξb2,∗ = (ξb2,∗1 , ξ
b2,∗
2 , µ
b2,∗) if 0 < log r < u(d˜∗,(1), d˜∗,(2)), where
ξb2,∗1 =
{
d˜∗,(1) d(1)max
1
2
1
2
}
, ξb2,∗2 =
{
0 d
(2)
max
1
2
1
2
}
, µb2,∗ =
{
1 2
1
2
1
2
}
,
(4) ξc,∗ = (ξc,∗1 , ξ
c,∗
2 , µ
c,∗) if log r ≥ 0 and log(r) > u(d˜∗,(1), d˜∗,(2)), where
ξc,∗1 =
{
d
(1)
max
1
}
, ξc,∗2 =
{
0 d˜∗,(2) d(2)max
1
3
1
3
1
3
}
, µc,∗ =
{
1 2
1
4
3
4
}
.
4 Example
In this section we assess the Bayesian D-optimal saturated designs characterised analyti-
cally in Section 3, via a numerical investigation of their performance in a situation where
these are not Bayesian D-optimal amongst all designs.
In particular, we consider the case of M = 2 different administration frequency groups
where the Emax regression function is used to model the dose-response relationship for
both groups. This choice of parametric model is frequent in dose-response studies see, for
example, Gabrielsson and Weiner (2007) and Thomas et al. (2014) for recent references.
It is also reasonable to assume that the placebo effect as well as the maximum effect that
can be achieved by the drug under investigation is the same between groups. Therefore,
the two Emax models are assumed to have common location and scale parameters which
corresponds to the case considered in Section 3.3. Furthermore, for illustration purposes,
the design spaces X1 and X2 are assumed to coincide with X1 = X2 = [0, 1] and also the
variances in both groups are assumed to be the same with σ21 = σ
2
2 = 1.
In what follows, the prior pi = p˜i1× p˜i2× p˜i(1)2 × p˜i(2)2 on the parameter space Θ = Θ1×Θ(1)2 ×
Θ
(2)
2 is used. The marginal priors p˜i1 and p˜i2 are set to the dirac measures δθ1 and δθ2 with
(θ1, θ2)
T = (0, 1)T , respectively, since the Emax model is linear in the location and scale
parameter and varying these parameters does not affect the information matrix. For the
priors p˜i
(1)
2 and p˜i
(2)
2 we use uniform distributions on the sets {0.20, 0.275, 0.35, 0.425, 0.50}
and {0.60, 0.675, 0.75, 0.825, 0.90}, respectively and thus, we have a total of P = 5 ·5 = 25
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different and equally probable parameter combinations. This corresponds to the case of
no preference for specific parameter combinations and thus under the concept of uniform
distributions there is no need for a prior to be specified, a step which is often difficult in
practice.
The scenario described above corresponds to the first case of Theorem 3.3 according to
which we calculate the Bayesian D-optimal design ξ∗ = (ξ∗1 , ξ
∗
2 , µ
∗) in the class Ξ24 of
saturated designs with respect to the prior pi which is given by
ξ∗1 =
{
0.00 0.1984207 1.00
1
3
1
3
1
3
}
, ξ∗2 =
{
0.742427
1
}
, µ∗ =
{
1 2
3
4
1
4
}
. (4.1)
Checking the inequalities (3.6) of the Equivalence Theorem 3.1 reveals that the design ξ∗
is not Bayesian D-optimal amongst all designs since the inequality is not satisfied for the
second administration frequency group (see Figure 1).
Χ1
τ 1
0.0 0.2 0.4 0.6 0.8 1.0
−
1.
5
−
1.
0
−
0.
5
0.
0
Χ2
τ 2
0.0 0.2 0.4 0.6 0.8 1.0
−
1.
5
−
1.
0
−
0.
5
0.
0
Figure 1: Illustration of Theorem 3.1 for the Bayesian D-optimal design ξ∗ in the class
Ξ24. The figures show the functions τ1 and τ2 defined by the left-hand side of inequality
(3.6), respectively. Left panel: τ1. Right panel: τ2.
Nevertheless, we further investigate the performance of the design ξ∗ given in (4.1) since
if it performs well then, as it is discussed in Section 3.1, it is preferred to the design that
is Bayesian D-optimal amongst all designs. The reason is that ξ∗ has minimum number
of support points, that is, it requires fewer doses to be utilised in the two administration
groups and thus it results in lower costs for the dose-response study without loosing much
information. We also note that finding the design that is Bayesian D-optimal amongst all
possible designs is computationally intensive even for the case of only two administration
14
frequency groups and to the best of our knowledge no analytical characterisations of these
designs, which would facilitate the evaluation, exist in the literature.
For the calculation of the design which is Bayesian D-optimal amongst all designs we used
the particle swarm optimisation algorithm (see Clerc (2006) for details) and the resulting
candidate design ξ∗,B = (ξ∗,B1 , ξ
∗,B
2 , µ
∗,B) is given by
ξ∗,B1 =
{
0.19982 1.00
0.50148 0.49852
}
, ξ∗,B2 =
{
0.00 0.56386 1.00
0.48649 0.26260 0.25091
}
,
µ∗,B =
{
1 2
0.48691 0.51309
}
.
(4.2)
As shown in Figure 2 both inequalities (3.6) of the Equivalence Theorem 3.1 are satisfied
for this candidate design and therefore, ξ∗,B given in (4.2) is in fact Bayesian D-optimal
amongst all designs.
Χ1
τ 1
0.0 0.2 0.4 0.6 0.8 1.0
−
1.
5
−
1.
0
−
0.
5
0.
0
Χ2
τ 2
0.0 0.2 0.4 0.6 0.8 1.0
−
1.
5
−
1.
0
−
0.
5
0.
0
Figure 2: Illustration of Theorem 3.1 for the Bayesian D-optimal design ξ∗,B. The figures
show the functions τ1 and τ2 defined by the left-hand side of inequality (3.6), respectively.
Left panel: τ1. Right panel: τ2.
We now assess the performance of a given design ξ (for a specific parameter vector θ) via
the D-efficiency defined as
eff(ξ,θ) =
det(M(ξ,θ))1/4
det(M(ξ∗(θ),θ))1/4
∈ [0, 1], (4.3)
where ξ∗(θ) is the locally D-optimal design with respect to the specific parameter vector
θ. The closer the D-efficiency of ξ is to 1, the fewer replicates are required for the design
ξ to be able to estimate the parameters with the same precision as ξ∗(θ).
15
Table 2 presents the D-efficiencies of ξ∗ and ξ∗,B, given in (4.1) and (4.2) respectively, for
the various parameter combinations resulting from the choice of prior pi. For example, for
the parameter vector θ = (0, 1, 0.2, 0.6) the D-efficiencies of ξ∗ and ξ∗,B are 97.52% and
97.31%, respectively.
θ
(1)
2
0.20 0.275 0.35 0.425 0.50
eff(ξ∗, (0, 1, θ(1)2 , θ
(2)
2 )) θ
(2)
2
0.6 97.52 99.20 98.68 96.94 94.25
0.675 97.96 99.65 99.50 98.26 96.23
0.75 98.07 99.76 99.81 98.91 97.37
0.825 97.94 99.62 99.77 99.10 97.90
0.90 97.62 99.30 99.51 98.97 98.02
eff(ξ∗,B, (0, 1, θ(1)2 , θ
(2)
2 )) θ
(2)
2
0.6 97.31 99.39 99.41 98.38 96.59
0.675 97.58 99.59 99.88 99.22 97.95
0.75 97.58 99.53 99.94 99.52 98.60
0.825 97.40 99.30 99.74 99.46 98.78
0.90 97.07 98.93 99.38 99.16 98.63
Table 2: The efficiencies (in %) of the Bayesian D-optimal design ξ∗ in the class Ξ24 and
of the Bayesian D-optimal design ξ∗,B for the P = 25 different parameter combinations.
Note that the D-efficiencies of both designs ξ∗ and ξ∗,B depicted in Table 2 are between
94% and 99%. Consequently, using either one of these two designs results in parameter
estimation with accuracy very close to the one the locally D-optimal design ξ∗(θ) would
have achieved. Moreover, for every parameter combination the D-efficiency of the design
ξ∗ which is Bayesian D-optimal only in the class of saturated designs is close to the
corresponding D-efficiency of the design ξ∗,B which is Bayesian D-optimal amongst all
designs. We therefore, conclude that our analytical characterisations of Bayesian D-
optimal saturated designs can be used without detriment thus reducing both the numerical
effort for design search as well as the cost of the dose-response study.
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A Appendix
Proof of Lemma 2.1:
16
Proof. Let ξ˜ = {d1, . . . , dm˜;ω1, . . . , ωm˜} be any saturated design on X = [0, dmax]. Also
let X˜ be the m˜ × m˜ matrix with jth column given by h˜(dj, θ˜), j = 1, . . . , m˜ and W˜ =
diag(ω1, . . . , ωm˜). Using this notation the information matrix defined in (2.2) and (2.3)
becomes
Mind(ξ˜, θ˜) = X˜W˜ X˜
T ,
and thus its determinant is given by
det
{
Mind(ξ˜, θ˜)
}
= [det{X˜}]2 det{W˜}.
Hence the Bayesian D-optimality criterion given in (2.4) becomes
Φp˜i(ξ˜) =
∫
Θ˜
(
2 log | det{X˜}|+
m˜∑
j=1
logωj
)
p˜i(dθ˜).
Maximising the above expression with respect to the weights ω1, . . . , ωm˜ under the con-
dition
∑m˜
j=1 ωj = 1 gives ωj =
1
m˜
for all j = 1, . . . , m˜ which proves the assertion.
Proof of Theorem 2.2:
Proof. From Lemma 2.1 we know that a Bayesian D-optimal saturated design has equal
weights. Therefore, let ξ˜ = {d1, d2, d3; 1/3, 1/3, 1/3} be an equally weighted three-point
design where 0 ≤ d1 < d2 < d3 ≤ dmax.
Theorem 4.1 in Dette et al. (2010) shows that for any of the models (2.5), (2.6) and (2.7)
the locally D-optimal design is supported at exactly three points two of which are the
end-points of the design space. Therefore, for any of these models the determinant of the
information matrix (2.2) of the equally weighted three-point design ξ˜ is decreasing with
d1 and increasing d3.
As a result, the Bayesian D-optimality criterion function given in (2.4) is also decreasing
with d1 and increasing with d3 and thus maximised at d
∗
1 = 0 and d
∗
3 = dmax. That is, for
any of the models (2.5), (2.6) and (2.7) a Bayesian D-optimal saturated design is always
supported at the end-points of the design space. The non-trivial support point can be
found by solving the equation
∂
∂d2
Φp˜i(ξ˜)|d1=0,d3=dmax = 0 ⇐⇒
∫
Θ˜2
∂
∂d2
(
log det{Mind(ξ˜, θ˜)}
)
|d1=0,d3=dmax p˜i2(dθ2) = 0,
for d2 ∈ (0, dmax). Using the appropriate information matrix for each of the three models
under consideration yields the equations of Theorem 2.2.
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Proof of Theorem 3.1:
Proof. For a fixed θ consider the set
Mθ = {M(ξpi,θ)|ξpi = (ξ1, . . . , ξM , µ) ∈ Ξ1(X1)× . . .× ΞM(XM)× Ξ({1, . . . ,M})} ,
where Ξ1(X1) × . . . × ΞM(XM) × Ξ({1, . . . ,M}) denotes the class of all designs on X1 ×
. . .×XM × {1, . . . ,M}, and note that Mθ is the convex hull of
Dθ =
{
M (i)(δd,θ) = hi(d,θ)h
T
i (d,θ)|i ∈ {1, . . . ,M}, d ∈ Xi
}
.
Using Theorem 3.3 in Dette et al. (2007), a design ξ∗pi = (ξ
∗
1 , . . . , ξ
∗
M , µ
∗) is Bayesian D-
optimal, with respect to the prior pi, in the class Ξ1(X1)× . . .×ΞM(XM)×Ξ({1, . . . ,M})
if and only if the inequality∫
Θ
tr{(M(ξ∗pi,θ))−1Eθ}pi(dθ) ≤ m,
holds for all matrices Eθ ∈Mθ.
Since Mθ is the convex hull of Dθ, it is sufficient to prove inequality for all Eθ ∈ Dθ.
Therefore, ξ∗pi is Bayesian D-optimal, with respect to the prior pi, in the class Ξ1(X1) ×
. . .× ΞM(XM)× Ξ({1, . . . ,M}) if and only if the inequality∫
Θ
tr{(M(ξ∗pi,θ))−1hi(d,θ)hTi (d,θ)}pi(dθ) ≤ m,
holds for all d ∈ Xi and i = 1, . . . ,M . Rewriting the above gives the inequalities of
Theorem 3.1.
Proof of Lemma 3.1:
Proof. The information matrix of the design ξpi can be rewritten as
M(ξpi,θ) = XWX
T ,
where
X =
(
h1(d
(1)
1 ), . . . , h1(d
(1)
m1
), . . . , hM(d
(M)
1 ), . . . , hM(d
(M)
mM
)
)
∈ Rm×m,
and
W = diag (λ1ω11, . . . , λ1ω1m1 , . . . , λMωM1, . . . , λMωMmM ) ∈ Rm×m.
Then the Bayesian D-optimality criterion function given in (3.5) becomes∫
Θ
log det{M(ξpi,θ)}pi(dθ) =
∫
Θ
(2 log | det{X}|+ log det{W})pi(dθ).
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Maximising
log det{W} =
M∑
i=1
log λi
mi∑
j=1
logωij,
under the conditions
∑M
i=1 λi = 1,
∑mi
j=1 ωij = 1 and
∑M
i=1 mi = m gives
λi =
mi
m
, ωij =
1
mi
, (i = 1, . . . ,M ; j = 1, . . . ,mi),
which proves the assertion.
Proof of Theorem 3.2
Proof. For the sake of transparency we restrict ourselves to the case M = 2 such that
m = 2q + 1.
By an application of Lemma 3.1 we obtain the following two candidates ξa = (ξa1 , ξ
a
2 , µ
a)
and ξb = (ξb1, ξ
b
2, µ
b) for a Bayesan D-optimal design in the class Ξ22q+1 with
ξa1 =
{
d
(1)
0 d
(1)
1 . . . d
(1)
q
1
q+1
1
q+1
. . . 1
q+1
}
, ξa2 =
{
d
(2)
1 . . . d
(2)
q
1
q
. . . 1
q
}
, µa =
{
1 2
q+1
2q+1
q
2q+1
}
,
ξb1 =
{
d
(1)
1 . . . d
(1)
q
1
q
. . . 1
q
}
, ξb2 =
{
d
(2)
0 d
(2)
1 . . . d
(2)
q
1
q+1
1
q+1
. . . 1
q+1
}
, µb =
{
1 2
q
2q+1
q+1
2q+1
}
.
We now evaluate the criterion values Φp˜i(ξ
a) and Φp˜i(ξ
a) and maximise them with respect
to the support points of the design ξa and ξb, respectively.
For the design ξa, the criterion value Φp˜i(ξ
a) can be rewritten by
Φp˜i(ξ
a) =
∫
Θ
(1)
2
(q + 1) log 1
σ21
+ (q + 1) log 1
q+1
+ 2 log |det{X1(d(1)0 , d(1)1 , . . . , d(1)q , θ(1)2 )}|p˜i(1)2 (dθ(1)2 )
+
∫
Θ
(2)
2
q log 1
σ22
+ q log 1
q
+ 2 log |det{X2(d(2)1 , . . . , d(2)q , θ(2)2 )}|p˜i(2)2 (dθ(2)2 ) + c(q),
(A.1)
where the (q + 1)× (q + 1)-dimensional matrix X1(d0, d1, . . . , dq, θ2) is given by
X1(d0, d1, . . . , dq, θ2) =
(
1 1 . . . 1
η0(d0, θ2) η0(d1, θ2) . . . η0(dq, θ2)
)
,
the q × q-dimensional matrix X2(d1, . . . , dq, θ2) is given by
X2(d1, . . . , dq, θ2) =
(
η0(d1, θ2) . . . η0(dq, θ2)
)
,
the constant c(q) only depends on the number of the non-common parameters q.
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The first term of the sum in (A.1) concides with Bayesian D-criterion for the individual
model of the form (3.8) with respect to the prior p˜i
(1)
2 and is therefore maximised by the
corresponding Bayesian D-optimal design ξ˜∗
p˜i
(1)
2
given by (3.10). Because of the conditions
in (3.9) the second term of the sum in (A.1) can be rewritten by∫
Θ
(2)
2
q log 1
σ22
+ q log 1
q
+ 2 log |det{X2(d(2)1 , . . . , d(2)q , θ(2)2 )}|p˜i(2)2 (dθ(2)2 )
=
∫
Θ
(2)
2
q log 1
σ22
+ q log 1
q
+ 2 log |det{X1(0, d(2)1 , . . . , d(2)q , θ(2)2 )}|p˜i(2)2 (dθ(2)2 ),
where the latter expression again corresponds to the Bayesian D-criterion for the individ-
ual model of the form (3.8) with respect to the prior p˜i
(2)
2 under the additional constraint
that the smallest support point d
(2)
0 = 0 is fixed to zero. Maximising this expression with
respect to the remaining q support points d
(2)
1 , . . . , d
(2)
q we receive that ξa2 = ξ
∗
2 where ξ
∗
2
is defined by (3.11).
A similar calculation for the criterion value Φp˜i(ξ
b) results in the maximising design ξb
where ξb1 = ξ
∗
1 and ξ
b
2 = ξ˜
∗
p˜i
(2)
2
which are defined in (3.11) and (3.10), respectively.
Taking into account that σ21 ≤ σ22 a comparison of the criterion values evaluated in ξa and
ξb results in Theorem 3.2.
Proof of Theorem 3.3:
Proof. Let ξpi = (ξ1, ξ2, µ) be an arbitrary design in the class Ξ
2
4 of saturated designs on
X1 ×X2 × {1, 2}. The information matrix of the design ξpi is given by
M(ξpi,θ) = λ
∫ d(1)max
0
h1(d,θ)h
T
1 (d,θ) dξ1(θ) + (1− λ)
∫ d(2)max
0
h2(d,θ)h
T
2 (d,θ) dξ2(θ),
where for Emax models
h1(d,θ) =
1
σ1
(
1,
d
d+ θ
(1)
2
,
d
(d+ θ
(1)
2 )
2
, 0
)T
, h2(d,θ) =
1
σ2
(
1,
d
d+ θ
(2)
2
, 0,
d
(d+ θ
(2)
2 )
2
)T
.
Let pi = p˜i1× p˜i2× p˜i(1)2 × p˜i(2)2 be a prior distribution on the parameter space Θ = Θ1×Θ2×
Θ
(1)
2 × Θ(2)2 . By an application of Lemma 3.1 we obtain the following candidate designs
for the Bayesian D-optimal design in the class Ξ24.
ξa1 =
{
d
(1)
1 d
(1)
2 d
(1)
3
1
3
1
3
1
3
}
, ξa2 =
{
d
(2)
1
1
}
, µa =
{
1 2
3
4
1
4
}
,
ξb1 =
{
d
(1)
1 d
(1)
2
1
2
1
2
}
, ξb2 =
{
d
(2)
1 d
(2)
2
1
2
1
2
}
, µb =
{
1 2
1
2
1
2
}
,
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ξc1 =
{
d
(1)
1
1
}
, ξc2 =
{
d
(2)
1 d
(2)
2 d
(2)
3
1
3
1
3
1
3
}
, µc =
{
1 2
1
4
3
4
}
.
We now evaluate the Bayesian D-optimality criterion function given in (3.5) for each of
these candidate designs and maximise it with respect to the support points.
For the design ξapi = (ξ
a
1 , ξ
a
2 , µ
a) the criterion function becomes
Φpi(ξ
a
pi) =
∫
Θ2×Θ(1)2
log
[
det
{
Mind(ξ
a
1 , θ2, θ
(1)
2 )
}]
(p˜i2 × p˜i(1)2 )(dθ2dθ(1)2 )
+
∫
Θ2×Θ(2)2
log
(1
4
)4
33
1
σ22
θ22
(
d
(2)
1
(d
(2)
1 + θ
(2)
2 )
2
)2 (p˜i2 × p˜i(2)2 )(dθ2dθ(2)2 ).
From Theorem 2.2 we have that the first term is maximised for d
(1)
1 = 0, d
(1)
3 = d
(1)
max and
d
(1)
2 = d˜
∗,(1) where the latter is a solution of equation (2.8) for the marginal prior p˜i(1)2 .
The second term is maximised at d
(2)
1 = d
∗,(2) which is a solution of the equation∫
Θ
(2)
2
1
d
− 2
d+ θ
(2)
2
p˜i
(2)
2 (dθ
(2)
2 ), (A.2)
in the interval [0, d
(2)
max]. Hence the design of the form ξapi maximising the Bayesian D-
optimality criterion function is ξa,∗pi = (ξ
a,∗
1 , ξ
a,∗
2 , µ
a,∗) where
ξa,∗1 =
{
0 d˜∗,(1) d(1)max
1
3
1
3
1
3
}
, ξa,∗2 =
{
d∗,(2)
1
}
, µa,∗ =
{
1 2
3
4
1
4
}
.
Following similar arguments we have that the design of the form ξcpi = (ξ
c
1, ξ
c
2, µ
c) max-
imising the Bayesian D-optimality criterion function is ξc,∗pi = (ξ
c,∗
1 , ξ
c,∗
2 , µ
c,∗) where
ξc,∗1 =
{
d∗,(1)
1
}
, ξc,∗2 =
{
0 d˜∗,(2) d(2)max
1
3
1
3
1
3
}
, µc,∗ =
{
1 2
1
4
3
4
}
,
and d∗,(1) and d˜∗,(2) are solutions of the equations (A.2) using the prior p˜i(1)2 and (2.8) using
the prior p˜i
(2)
2 respectively.
For the D-optimality of the design ξbpi = (ξ
b
1, ξ
b
2, µ
b) we note that the smallest support
points d
(1)
1 and d
(2)
1 of the components ξ
b
1 and ξ
b
2 must satisfy d
(1)
1 + d
(2)
1 > 0 otherwise
the determinant of the information matrix vanishes. Hence there exist two possibilities
corresponding to the cases d
(1)
1 = 0 or d
(2)
1 = 0. That is,
ξb11 =
{
0 d
(1)
2
1
2
1
2
}
, ξb12 =
{
d
(2)
1 d
(2)
2
1
2
1
2
}
, µb1 =
{
1 2
1
2
1
2
}
,
ξb21 =
{
d
(1)
1 d
(1)
2
1
2
1
2
}
, ξb22 =
{
0 d
(2)
2
1
2
1
2
}
, µb2 =
{
1 2
1
2
1
2
}
.
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Now following the same arguments as for the previous candidate designs we conclude that
the designs ξb1,∗pi = (ξ
b1,∗
1 , ξ
b1,∗
2 , µ
b1,∗) and ξb2,∗pi = (ξ
b2,∗
1 , ξ
b2,∗
2 , µ
b2,∗) maximising the Bayesian
D-optimality criterion function, among all designs of the corresponding form, are given
by
ξb1,∗1 =
{
0 d∗,(1)
1
2
1
2
}
, ξb1,∗2 =
{
d˜∗,(2) d(2)max
1
2
1
2
}
, µb1,∗ =
{
1 2
1
2
1
2
}
,
and
ξb2,∗1 =
{
d˜∗,(1) d(1)max
1
2
1
2
}
, ξb2,∗2 =
{
0 d∗,(2)
1
2
1
2
}
, µb2,∗ =
{
1 2
1
2
1
2
}
,
respectively, where d∗,(i) and d˜∗,(i) are solutions of the equations (A.2) and (2.8) respec-
tively using the prior p˜i
(i)
2 , i = 1, 2.
Finally the assertion of the theorem follows by straightforward calculations comparing the
Bayesian D-optimality criterion function of the designs ξa,∗pi , ξ
b1,∗
pi , ξ
b2,∗
pi , ξ
c,∗
pi in the different
scenarios.
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